Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Study Number: S2013
Study Summary:
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Status: Open
Peoria, Bloomington, Galesburg, Pekin, Washington
Study Coordinator(s)
- Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
- Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
- Navigator Angie, 309-243-3613, aearles@illinoiscancercare.com
